Saturday, 22 November 2014

My previous 3 posts of info was gleened from MS-UK, a far superior sit than MSS

No question

Of course there is a higher risk, Candida is linked to all cancer, paticularly breast and protrate

The study reported in the European Journal of Neurology claims that people suffering from multiple sclerosis, an autoimmune disease affecting nerves in brain and spinal cord, have a higher risk of developing cancer, especially breast cancer.

Studies conducted earlier claimed that people with autoimmune disease may suffer from a greater risk of developing cancer but most of the studies detected no association between multiple sclerosis (MS) and cancer. Since this latest finding contradicts the previous findings, researchers say that additional research is required to determine whether or not there is a link between the disease and cancer.

For the study, researchers evaluated the data retrieved from the National Health Insurance System of Taiwan. They assessed the information on 1292 people who were diagnosed with MS between 1997 and 2010. They further matched each MS patient with four healthy people who were not diagnosed with the condition.

MS that is not considered as a fatal disease is a chronic and unpredictable disease. It normally affects people between the ages of 20 and 50. This autoimmune disease causes extreme fatigue, blindness, paralysis, poor coordination and more. There are more than 2.5 million people around the world living with MS.

This investigation was led by Li-Min Sun, MD, of the Zuoying Branch of Kaohsiung Armed Forces General Hospital in Kaohsiung, Taiwan.

"Our study was a nationwide population-based cohort study, and it revealed unexpected findings," said Dr. Sun

The researchers noticed that those with MS suffered 85 percent higher risk of developing cancer when compared to the control group. There was a twofold higher risk of developing breast cancer when compared to the control group.

This study suggests that those with MS should be monitored closely in order to ensure the early detection of cancer.

Unsure of why the results of this study differs from the previous studies, Dr. Sun notes says, "The underlying genetic and environmental factors in Taiwan, which differ from those of western countries, might play an undetermined role. Additional large-scale studies will help improve our understanding."

Source: Science World Report © 2014 ScienceWorldReport.com (16/01/14

Time and money again wasted - EBV causes CFS, a misaligned Atlas causes fatigue, as also does candida


Researchers presented a new mouse model for fatigue at the 2014 Society for Neuroscience meeting. The model is the first of its kind and works by manipulating the pro-inflammatory cytokine interleukin-1β.

There’s a new animal model coming down the pike that may be of use to multiple sclerosis researchers. At the Society for Neuroscience (SfN) annual meeting in Washington, D.C., researchers announced that they have developed a new mouse model for fatigue. This is the first mouse model to isolate fatigue from other symptoms.

Fatigue is said to be the most common and debilitating symptom of multiple sclerosis. It’s characterised less as sleepiness and more as an inability to function normally, even if the motivation is there.

“Surprisingly, this is an underrepresented area of research,” Mary Harrington, Ph.D., of Smith College said at an SfN press conference. “There is little to no understanding of what is the underlying neurobiology of fatigue.”

The model

The researchers began by activating the pro-inflammatory cytokine interleukin-1β (IL-1β) in young, middle-aged, and aged female mice. The animals demonstrated signs of fatigue, without any other signs of sickness (Bonsall et al, 2014). Middle-aged (6 to 12 months old) and aged mice (18 to 24 months old) almost completely stopped voluntary wheel-running compared to their baseline activity. They did not, however, show signs of fever, muscle ache, or anhedonia (decreased pleasure-seeking activity). The researchers saw no significant change in the young (3- to 5-month-old) mice.

The researchers also found that the treatment did not seem to act upon the neurotransmitter orexin to induce fatigue. Orexin is thought to mediate arousal and wakefulness. Unsurprisingly, the mice also did not respond well to medications that work on the arousal system, such as modafinil (Provigil, Teva Pharmaceuticals) or methylphenidate (Ritalin, Concerta, and others), a drug commonly prescribed to treat attention deficit hyperactivity disorder.

In an interview with MSDF, Harrington, whose background is in studying circadian rhythms, said that patients often don’t report fatigue to their physician because it seems hopeless. Currently, no effective treatments exist for fatigue.

One possible reason that it’s been so difficult to get a handle on the biology of fatigue is that researchers may have been looking in the wrong place. It could be that fatigue originates in the immune system, not in the nervous system. Harrington pointed out that the diseases characterized by fatigue have one major common denominator: inflammation. Harrington said that she decided to target IL-1β after reviewing the literature and work done in a model for fatigue used in rats.

In the rat model, researchers give the rats a compound called PolyIC. “It’s a viral mimic so your body thinks you’re having a viral infection,” Harrington said to MSDF. “When researchers tried to reverse the effects of PolyIC they realised that they could do it with a blocker of interleukin-1β.”

Harrington said that more work needs to be done to verify her work. But she hopes the model can help illuminate key players in generating fatigue and can be used for drug screening. She said she hopes that MS researchers will use it to help defeat the most debilitating symptom of MS.

Key open questions

How can this model be used to best serve MS research? Can it be combined with experimental autoimmune encephalomyelitis (EAE)? Why does fatigue result from inflammation, and how can it be best treated?

Disclosures and sources of funding

Harrington’s work was supported by NIH grant R21NR012845. She reported no conflicts of interest.

References

Editors' Pick
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments BONSALL D, Kim H, PETRONZIO AM, MOLYNEUX PC, SCAMMELL TE, HARRINGTON ME Society for Neuroscience 2014. 11/18/2014.

Source: Multiple Sclerosis Discovery Forum Copyright © 2014 MGH

Another pit to waste money on - its a misaligned Atlas and Candida that cause cognative failure


The Cognitive Rehabilitation for Attention and Memory trial (CRAMMS), a major study to be conducted on patients with multiple sclerosis, was recently awarded £1,167,000 by the National Health Service (NHS), through its Health Technology Assessment (HTA) Program.

The study, which is expected to be the largest trial of its kind in the United Kingdom, is designed to examine MS patients’ cognitive rehabilitation capacities and determine if a group of cognitive rehabilitation programs is able to improve patients’ quality of life.

This symptom management clinical trial for MS is being conducted because so many patients experience difficulties in cognitive processes, including loss in memory, decision making, and concentration, and there are currently few effective treatments available for the management of these symptoms. Therefore, the CRAMMS trial is expected to be able to advance the development of new therapies to improve the lives of patients with these problems.

The trial, which is expected to occur between September of 2014 and August of 2018 at four centres in Nottingham, Sheffield, Liverpool, and Birmingham, is currently enrolling patients, who must be diagnosed with MS and between the ages of 18 and 70 years old. During the trial, participants will be enrolled over the course of 16 months and will participate in either weekly group cognitive rehabilitation sessions with a psychologist and their usual care, or just their usual care. The investigators will then evaluate and compare the effects on the two groups.

“We do not know whether taking part in the study will help but we expect that some people will find the intervention helps them cope with memory and attention problems,” the website of the trial states. “However, the information we get from this study may help us to treat people with MS and attention and memory problems better in future. There are no particular risks involved in taking part in this study.”

In addition, the trial is also expected to raise particular attention and investment into other research focused to the disease.

Source: Multiple Sclerosis News Today © Copyright 2014 BioNews Services

I think charitable organizations have becomeme to fucussed

on money raising to sustain their own existance, they have forgotten their reason, and that is to investigate ALL alternatives and they totally miss the point, they are to busy congratulating themselves on how much money they have raised, thus keeping us  dependant upon them, which is truly a selfish act.

Repost - This best describes my physical experience

Thursday, 14 August 2014

Robin Williams died because he was diagnosed with Parkinson's a condition that just doesn't exist

Along with MS and many other neurological conditions such as cerebral Palsy. It is all down to Atlas misalignment. What happens is you lose your centre, your cervical spine (neck) becomes weak and it becomes impossible to support the heaviest organ of the body the brain. It is not only important that the Atlas is in the proper  position  but because it is not, the axis is affected and it is not possible to rotate it to view all four corners of the room that surrounds you.

Atlas misalignment can affect any part of the body all senses, vision  hearing sinuses and speech. your muscles waste to a degree you have no physical  strength. your finger prints lose their traction and resistance thus making your hands slip on any surface and will not support your weight

Your core is the hinge to the body, if a hinge becomes faulty or not well oiled to function, the door becomes difficult to open or close.

A misaligned Atlas has numerous knock on effect to the rest of the body, rendering it sick. but this sickness can be cured. All messages pass through the neck from the brain or vice versa but to do that efficiently  it cannot be compromised in any way our blood flow is altered hence CCSVI people mistakenly diagnosed with MS have this as a symptom, hence having stents fitted, only to eventually close and revert back and why does this happen. Because a failure to address the fundamental issue of misalignment causes the problem to continue.

There has been scare mongering against Chiropractic neck adjustment due to a patient apparently had a stroke, but I believe Atlas misalignment may contribute to causing a stroke in the first place.

Friday, 21 November 2014

Why is this on Cancer Reearch UK - I totally disagree with what they say, cancer is a fungus and caused by Candida, and bicarbonate can have a positive affect

Myth 5: Cancer is a fungus – and sodium bicarbonate is the cure

Ask any pathologist - cancer cells aren’t fungal
This ‘theory’ comes from the not-very-observant observation that “cancer is always white”.
One obvious problem with this idea – apart from the fact that cancer cells are clearly not fungal in origin – is that cancer isn’t always white. Some tumours are. But some aren’t. Ask any pathologist or cancer surgeon, or have a look on Google Image search (but maybe not after lunch…).
Proponents of this theory say that cancer is caused by infection by the fungus candida, and that tumours are actually the body’s attempt at protecting itself from this infection.
But there’s no evidence to show that this is true.
Furthermore, plenty of perfectly healthy people can be infected with candida – it’s part of the very normal array of microbes that live in (and on) all of us. Usually our immune system keeps candida in check, but infections can get more serious in people with compromised immune systems, such as those who are HIV-positive.
The ‘simple solution’ is apparently to inject tumours with baking soda (sodium bicarbonate). This isn’t even the treatment used to treat proven fungal infections, let alone cancer. On the contrary, there’s good evidence that high doses of sodium bicarbonate can lead to serious – even fatal – consequences.
Some studies suggest that sodium bicarbonate can affect cancers transplanted into mice or cells grown in the lab, by neutralising the acidity in the microenvironment immediately around a tumour. And researchers in the US are running a small clinical trial investigating whether sodium bicarbonate capsules can help to reduce cancer pain and to find the maximum dose that can be tolerated, rather than testing whether it has any effect on tumours.
As far as we are aware, there have been no published clinical trials of sodium bicarbonate as a treatment for cancer.
It’s also worth pointing out that it’s not clear whether it’s possible to give doses of sodium bicarbonate that can achieve any kind of meaningful effect on cancer in humans, although it’s something that researchers are investigating.
Because the body strongly resists attempts to change its pH, usually by getting rid of bicarbonate through the kidneys, there’s a risk that doses large enough to significantly affect the pH around a tumour might cause a serious condition known as alkalosis.

One estimate suggests that a dose of around 12 grams of baking soda per day (based on a 65 kg adult) would only be able to counteract the acid produced by a tumour roughly one cubic millimetre in size. But doses of more than about 30 grams per day are likely to cause severe health problems – you do the maths.